Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Shahram Hejazi
AddedMar 31, 2024
UpdatedMay 31, 2026
Shahram Hejazi

Shahram Hejazi

CEO, BioAdvance

CrunchbaseLinkedIn

Shahram Hejazi's Career

BioAdvance
BioAdvance

Radnor, PA, US

CEO· C-Suite · Management
Optimeos Life Sciences
Optimeos Life Sciences

Princeton, NJ, US

Co-Founder & CEO· C-Suite · Management
InfraScan
InfraScan

Philadelphia, PA, US

Board Member· Board
Halo Labs
Halo Labs

Philadelphia, PA, US

Board Member· Board
Integral Molecular
Integral Molecular

Philadelphia, PA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Shahram Hejazi's Career

BioAdvance
BioAdvance
Investment FirmInvestment Firm$14.8M302003Radnor, PA, US
CEO· C-Suite · Management
Optimeos Life Sciences
Optimeos Life Sciences
Angel$631k52016Princeton, NJ, US
Co-Founder & CEO· C-Suite · Management

Leadership at Optimeos Life Sciences

Bob Prud'hommeBob Prud'hommeCo-Founder
InfraScan
InfraScan
Public$500k92004Philadelphia, PA, US
Board Member· Board

Leadership at InfraScan

Baruch Ben DorBaruch Ben DorBoard Member
Banu OnaralBanu OnaralBoard Member
Sandeep NaikSandeep NaikFounder
Arie CohenArie CohenBoard Member
Britton ChanceBritton ChanceBoard Member
Kambiz PourrezaeiKambiz PourrezaeiBoard Member

Similar to InfraScan

Infrared Imaging SystemsInfrared Imaging SystemsMarysville, OH, USMedical Devicesest. 2001Infrared Imaging SystemsMarysville, OH, US · est. 2001

INRIS: A medical device manufacturer enhancing vascular access accuracy with innovative infrared imaging technology.

Angel · $39.9k6
Infrared ComponentsInfrared ComponentsUtica, NY, USThermal Imagingest. 2003Infrared ComponentsUtica, NY, US · est. 2003

Infrared Components Corp: NY-based manufacturer of thermal imaging products and information services.

Angel · $171.8k20
Sense DiagnosticsSense DiagnosticsCincinnati, OH, USMedical Devicesest. 2014Sense DiagnosticsCincinnati, OH, US · est. 2014

Sense Neuro Diagnostics develops non-invasive tech for rapid stroke detection and brain injury monitoring.

Angel · $14.2M15
Innovative Trauma CareInnovative Trauma CareSan Antonio, TX, USMedical Devicesest. 2010Innovative Trauma CareSan Antonio, TX, US · est. 2010

Innovative Trauma Care: A medical device company specializing in hemorrhage solutions.

Angel · $12.3M16
Halo Labs
Halo Labs
Series C$26.8M402011Philadelphia, PA, US
Board Member· Board

Leadership at Halo Labs

Bill SniderBill SniderBoard Member
Rick GordonRick GordonCEO
Robert HartRobert HartCo-Founder
Bernardo CordovezBernardo CordovezCo-Founder
Integral Molecular
Integral Molecular
Pre-Seed$13.4M302001Philadelphia, PA, US
Board Member· Board

Leadership at Integral Molecular

Benjamin DoranzBenjamin DoranzCo-Founder
Martin LehrMartin LehrBoard Member
Joseph RuckerJoseph RuckerCo-Founder
Gregory AdamsGregory AdamsBoard Member

Similar to Integral Molecular

MSM Protein TechnologiesMSM Protein TechnologiesWoburn, MA, USAntibody Drugs, Drug Discoveryest. 2005MSM Protein TechnologiesWoburn, MA, US · est. 2005

MSM Protein Technologies: A US-based pharmaceutical firm specializing in antibody drugs and protein development.

Angel · $250k7
Indi MolecularIndi MolecularCulver City, CA, USOncology Therapeuticsest. 2013Indi MolecularCulver City, CA, US · est. 2013

Indi Molecular: A life sciences company specializing in developing superior synthetic peptide molecules.

Series A · $13.3M5
OmniAbOmniAbEmeryville, CA, USAntibody Discoveryest. 2021OmniAbEmeryville, CA, US · est. 2021

OmniAb: Your pharmaceutical partner in discovering next-generation therapeutics through diverse antibody repertoires.

Public · $70M175
IdbiologicsIdbiologicsNashville, TN, USAntibodies, Therapeuticsest. 2017IdbiologicsNashville, TN, US · est. 2017

IDBiologics: Pioneering infectious disease treatment through rapid discovery and optimization of human monoclonal antibodies.

Seed · $4.8M7

Shahram Hejazi's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakHaeil YiHaeil YiCo-Founder · DunamuLee Sirg-OoLee Sirg-OoCEO · Dunamu

People Similar to Shahram Hejazi

Juan EnriquezJuan EnriquezFounder & CEO · BiotechonomyKenneth LoschKenneth LoschCEO · Advanced Green InnovationsMarcus Meadows-SmithMarcus Meadows-SmithBoard Member · Crop EnhancementVenkat KrishnanVenkat KrishnanCEO · BionpharmaJohannes FruehaufJohannes FruehaufCo-Founder · Mission BioCapitalTravis MurdochTravis MurdochCEO · HI-Bio